NCT00989027

Impact of Uterotonic Agents on Isolated Human Myometrium

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 56 (actual)
• Sponsor: Samuel Lunenfeld Research Institute, Mount Sinai Hospital · Academic / Other
• Sex: Female
• Age: —
• Healthy volunteers: Accepted

Summary

The purpose of this study is to compare the ability of a sample of uterine muscle tissue to contract in the presence of various drugs. The drugs studied are typically used to contract the uterus when a pregnant patient continues to bleed after delivery. Amongst the uterotonic drugs (used to contract the uterus), namely oxytocin, ergonovine and carboprost, the most effective one to use is not known. The investigators will be testing uterine muscle samples in the presence of these drugs at various concentrations, to see what their contractility measures over time, as compared with a control sample, in which no drugs will be applied.

Detailed description

Postpartum hemorrhage (PPH) is a major cause of maternal mortality and morbidity. In 80% cases of PPH, the primary cause is failure of the uterus to contract after delivery of the baby, which then requires further treatment of the mother with uterotonic drugs (drugs used to contract uterus and thus prevent bleeding). Patients participating in this study will be asked to donate a very small sample of uterine tissue during Cesarean section, which will be tested for the ability to contract after treatment with various uterotonic drugs (oxytocin, ergonovine and carboprost) in the laboratory. This information will help us know the effect of these drugs by comparing the contractile capability of the uterine tissue.

Conditions

• Postpartum Hemorrhage

Interventions

Type	Name	Description
DRUG	Oxytocin	Oxytocin, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
DRUG	Ergonovine	Ergonovine, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
DRUG	Carboprost	Carboprost, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
DRUG	Oxytocin and Ergonovine	Oxytocin and Ergonovine, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
DRUG	Oxytocin and Carboprost	Oxytocin and Carboprost, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.

Timeline

• Start date: 2007-06-01
• Primary completion: 2013-08-01
• Completion: 2013-08-01
• First posted: 2009-10-02
• Last updated: 2014-02-20

Locations

1 site across 1 country: Canada